


# Innovating to end malaria

Unitaid's malaria portfolio has doubled during 2015–2018 and will continue to expand through 2020




## Our recent game-changing investments include:



### Preventive treatments

Protection for pregnant women in sub-Saharan Africa and long-acting seasonal prevention for small children in the Sahel region


**\$ 61 m**



### Vector control tools

Protecting families with new insecticide treated nets and indoor sprays, mosquito-repellent sheets for indoor and outdoor protection, and a drug for humans and livestock that kills mosquitoes

**\$ 190 m**



### Vaccine

Piloting the world's first malaria vaccine in three high-malaria countries in Africa

**\$ 10 m**



### Integrated fever approaches

Increasing access to portable devices that can detect signs of life-threatening febrile illnesses (e.g. severe malaria and severe pneumonia)

**\$ 43 m**



### Treatment

Expanding access to severe malaria interventions including rectal artesunate as an emergency referral measure

**\$ 33 m**



### Our portfolio keeps growing

Future investments being explored include expanding integrated approaches, eliminating *Plasmodium vivax* malaria and increasing access to preventive treatments for infants. We continue to provide funding for WHO's prequalification program.